Karyopharm Therapeutics Inc. (NASDAQ:KPTI) is scheduled to release its earnings data before the market opens on Thursday, November 2nd. Analysts expect Karyopharm Therapeutics to post earnings of ($0.64) per share for the quarter.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Tuesday, August 8th. The company reported ($0.64) EPS for the quarter, meeting the consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. During the same period in the prior year, the business posted ($0.84) earnings per share. The business’s revenue was down 95.0% compared to the same quarter last year. On average, analysts expect Karyopharm Therapeutics to post $-2.65 EPS for the current fiscal year and $-2.11 EPS for the next fiscal year.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) traded up 1.70% during mid-day trading on Friday, reaching $10.16. 132,134 shares of the company traded hands. Karyopharm Therapeutics Inc. has a 52-week low of $6.27 and a 52-week high of $14.63. The firm’s 50-day moving average is $11.01 and its 200 day moving average is $9.82. The stock’s market capitalization is $478.92 million.

In other Karyopharm Therapeutics news, Director Mansoor Raza Mirza sold 2,882 shares of the firm’s stock in a transaction on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the sale, the director now directly owns 2,882 shares in the company, valued at $31,702. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 10,695 shares of company stock worth $118,950 over the last quarter. 14.71% of the stock is currently owned by company insiders.

WARNING: “Karyopharm Therapeutics Inc. (KPTI) Set to Announce Earnings on Thursday” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/28/karyopharm-therapeutics-inc-kpti-set-to-announce-earnings-on-thursday.html.

A number of equities analysts have commented on KPTI shares. Jefferies Group LLC reaffirmed a “buy” rating and issued a $19.00 price objective (up previously from $16.00) on shares of Karyopharm Therapeutics in a report on Thursday, August 10th. BidaskClub upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. ValuEngine cut Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 18th. Zacks Investment Research cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, July 18th. Finally, Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company. Karyopharm Therapeutics has an average rating of “Buy” and a consensus target price of $15.38.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Earnings History for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.